Category: isoquinoline

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.34784-02-6,3-Bromoisoquinoline,as a common compound, the synthetic route is as follows.

General procedure: A suspension of intermediate 15(104.0 mg, 0.4 mmol), 7-bromoquinoline (124.8 mg, 0.6 mmol), t-BuONa (96.0 mg, 1.0 mmol), Pd2(dba)3 (18.0 mg, 0.019 mmol) andX-phos (9.6 mg, 0.02 mmol) in PhMe (2.8 ml) was degassed under astream of nitrogen over 10 min. The mixture was heated to 110 Cand stirred overnight. The resulting mixturewas filtered off and thesolution was concentrated under vacuum. The crude product waspurified by column chromatography on silica using a solvent of 60%ethyl acetate in hexanes. Compound 3l was obtained as a lightgreen solid (Yield: 60.0 mg, 38.8%).

34784-02-6, The synthetic route of 34784-02-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Yu, Jiang; Zhou, Peiting; Hu, Mingxing; Yang, Liuqing; Yan, Guoyi; Xu, Ruixue; Deng, Yufang; Li, Xinghai; Chen, Yuanwei; European Journal of Medicinal Chemistry; vol. 182; (2019);,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

3336-43-4, 1-Chloroisoquinolin-4-ol is a isoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step 1: Preparation of 1-chloro-4-methoxyisoquinoline To a solution of 1-chloroisoquinolin-4-ol (5.0 g, 27.8 mmol) in acetonitrile (50 mL) was added TMS-diazomethane (12.73 g, 111.2 mmol) at 0 C. The reaction mixture was allowed to come to room temperature and stirred for 2 h. Solvent was evaporated under reduced pressure to get crude compound. The crude compound was purified by silica gel chromatography to get 1-chloro-4-methoxyisoquinoline (2.5 g, 46.4%) as off-white solid. 1H NMR (400 MHz, CD3OD): delta ppm 8.29-8.17 (m, 2H), 7.97 (s, 1H), 7.91-7.82 (m, 2H), 4.05 (s, 3H); MS: MS m/z 194.7 (M++1)., 3336-43-4

3336-43-4 1-Chloroisoquinolin-4-ol 4281882, aisoquinoline compound, is more and more widely used in various fields.

Reference£º
Patent; Bristol-Myers Squibb Company; Rajamani, Ramkumar; Renduchintala, Kishore V.; Sarkunam, Kandhasamy; Nagalakshmi, Pulicharla; Meanwell, Nicholas A.; Scola, Paul Michael; US2013/142754; (2013); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.23687-26-5,6-Aminoisoquinoline,as a common compound, the synthetic route is as follows.

Example 7 Preparation of (R)-tert-butyl 2-(isoquinolin-6-ylamino)-2-oxo-1-phenylethyl(methyl)carbamate (E7) To (R)-2-(tert-butoxycarbonyl(methyl)amino)-2-phenylacetate (E6) in DMF was added EDC, DMAP and 6-aminoisoquinoline. This mixture was stirred for 4 hours and the reaction was washed with NaHCO3 (sat), extracted with EtOAc, dried (Na2SO4), filtered and evaporated. Column chromatography (SiO2, Hexanes/EtOAc) gave pure (R)-tert-butyl 2-(isoquinolin-6-ylamino)-2-oxo-1-phenylethyl(methyl)carbamate (E7)., 23687-26-5

As the paragraph descriping shows that 23687-26-5 is playing an increasingly important role.

Reference£º
Patent; Aerie Pharmaceuticals, Inc.; US2009/186917; (2009); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

23687-26-5, 6-Aminoisoquinoline is a isoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

K3P04 (0.449 g, 2.117 mmol), Pd2(dba)3 (0.040 g 0.0441 mmol) and Xantphos (0.043 g, 0.0735 mmol) were added to a solution of intermediate 16 (0.153 g, 0.809 mmol) in THF (4 mL) while nitrogen was bubbling through the mixture. After 10 min, isoquinolin-6-amine (0.106 g, 0.735 mmol) was added and the mixture was stirred at rt for 10 min. Then, the mixture was heated at 100 ¡ãC for 16 h. The mixture was washed with aq. sat. NaHC03 and extracted with EtOAc. The combined org layers were dried over MgSC , filtered and the solvent was evaporated in vacuo. The crude product was purified by flash column chromatography; (silica; EtOAc in Heptane, 0/100 to 35/65). The desired fractions were collected and concentrated in vacuo. The residue was dissolved in DCM, HC1 (5 N in 2-propanol) was added and the mixture was concentrated in vacuo. The residue was triturated with DIPE and filtered to yield compound 10 as a yellow solid (0.147 g, 47percent). ‘H NMR (300 MHz, DMSO-d6) delta ppm 2.00 – 2.23 (m, 2 H) 4.16 (t, J=6.2 Hz, 2 H) 4.63 (dt, J=47.3, 5.8 Hz, 2 H) 7.18 (d, J=8.9 Hz, 1 H) 7.51 (dd, J=8.9, 3.0 Hz, 1 H) 7.91 (dd, J=9.2, 1.4 Hz, 1 H) 8.07 (d, J=6.7 Hz, 1 H) 8.13 (d, J=2.7 Hz, 1 H) 8.28 (d, J=9.1 Hz, 1 H) 8.34 (d, J=6.6 Hz, 1 H) 8.63 (s, 1 H) 9.41 (s, 1 H) 10.44 (s, 1 H), 23687-26-5

As the paragraph descriping shows that 23687-26-5 is playing an increasingly important role.

Reference£º
Patent; JANSSEN PHARMACEUTICA NV; ANDRES-GIL, Jose, Ignacio; BORMANS, Guy, Maurits, R.; DECLERCQ, Lieven, Denis, Herwig; FIERENS, Katleen; LEENAERTS, Joseph, Elisabeth; MOECHARS, Diederik, Willem, Elisabeth; ROMBOUTS, Frederik, Jan, Rita; KOLB, Hartmuth; ZHANG, Wei; (67 pag.)WO2018/15307; (2018); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.891785-28-7,6-Bromoisoquinolin-3-amine,as a common compound, the synthetic route is as follows.

891785-28-7, Step 1 To a solution of 6-bromoisoquinolin-3-amine (XX)(3.0 g, 13.45 mmol)and 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)isonicotinic acid (XII)(10.62 g, 32.94 mmol)in DCE was added DMAP (1.64 g, 13.45 mmol), DIPEA (7.03 mL, 40.35 mmol), HATU (12.32 g, 32.4 mmol)to DCE (67.2 mL)stirred at 75 C. for 16 hours. The solvent was removed under vacuum and putified by silica gel (40 g)using 0 to 50% EtOAc/hexanes to produce tert-butyl 4-((4-((6-bromoisoquinolin-3-yl)carbamoyl)pyridin-2-yl)oxy)piperidine-1-carboxylate (XLIV)as an off-white solid (4.37 g, 8.29 mmol, 61.6% yield). ESIMS found for C25H27BrN4O4 m/z 426.1 (M-Boc).

As the paragraph descriping shows that 891785-28-7 is playing an increasingly important role.

Reference£º
Patent; Samumed, LLC; KC, Sunil Kumar; Mak, Chi Ching; Eastman, Brian Walter; Cao, Jianguo; Bollu, Venkataiah; Mittapalli, Gopi Kumar; Chiruta, Chandramouli; (218 pag.)US2017/313682; (2017); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.6624-49-3,Isoquinoline-3-carboxylic acid,as a common compound, the synthetic route is as follows.

General procedure: To the resin 13 (560 mg) in DMF (2.5 mL) were added a solutionof the appropriate Fmoc-protected amino acid (see Tables 1?3)(0.3 M), PyBOP (0.3 M) and HOBt (0.3 M) in dry DMF (4.2 mL). Thesuspensions were stirred for 3 min and then DIPEA (0.6 M) wasadded. The suspensions were stirred for 3 h under an argon atmosphereat rt. The resins were washed successively with DCM(150 mL), MeOH (120 mL), DCM (75 mL) and dried overnight undervacuum to give resins 14, each bearing an appropriate Fmoc-protectedamino acid. To the resins 14 (161 mg, 0.13 mmol) wereadded a solution of piperidine (20percent, v/v) in DCM (2.1 mL) and themixtures were stirred for 1 h at rt. After filtration, the resins werewashed successively with DCM (50 mL), MeOH (45 mL), DCM(25 mL) and dried under vacuum to give resins 15. Portions(65 mg) of resins 15 were placed in reactor wells (12 mL) of anautomated synthesizer reaction block (40-well format) (AdvancedChemTech). To each well was added a solution of appropriate carboxylicacid (see Tables 1?3) (0.3 M), PyBOP (0.3 M) and HOBt 6-Cl(0.3 M) and DIPEA (0.6 M) in dry DMF (2 mL). The suspensionswere vortexed at 300 rpm over a period of 5 h under an argonatmosphere. The wells were then filtered to remove the reactivesolution from the resins 16 and washed successively with THF,DCM, MeOH and DCM., 6624-49-3

Big data shows that 6624-49-3 is playing an increasingly important role.

Reference£º
Article; Talbot, Amelie; Maltais, Rene; Kenmogne, Lucie Carolle; Roy, Jenny; Poirier, Donald; Steroids; vol. 107; (2016); p. 55 – 64;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

34784-04-8, 5-Bromoisoquinoline is a isoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

EXAMPLE 57B 5-bromo-8-nitroisoquinoline The diethyl ether solution from Example 57A was treated with potassium nitrate (10.1 g, 100 mmol). After stirring for one hour, The mixture was poured onto ice and neutralized with concentrated ammonium hydroxide (300 ml). The crude product was collected by filtration, dried, and recrystalization from methanol to provide the title compound (8.83 g).

34784-04-8, The synthetic route of 34784-04-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Lee, Chih-Hung; Bayburt, Erol K.; DiDomenico JR., Stanley; Drizin, Irene; Gomtsyan, Arthur R.; Koenig, John R.; Perner, Richard J.; Schmidt JR., Robert G.; Turner, Sean C.; White, Tammie K.; Zheng, Guo Zhu; US2003/158188; (2003); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.6624-49-3,Isoquinoline-3-carboxylic acid,as a common compound, the synthetic route is as follows.

6624-49-3, A solution of 2 (519.0 mg, 3.0 mmol) and mono-N-Boc-protected TREN (3) (246.0 mg, 1.0 mmol) in DMF (50 mL) was prepared at room temperature under nitrogen. While stirring, DMTMM (4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholiniumchloride) (830.1 mg, 3 mmol) and NMM (N-methylmorpholine) were added (dropwise 2-3 ml) to get a pH of about 9. Then solution was diluted with methanol (10 ml) and allowed to stir at room temperature. After 12 h, the solvent was removed in vacuo and the residue was dissolved in ethyl acetate. After removal of solvent the crude product was purified by column chromatography using silica gel and CH2Cl2:MeOH (20:1). The product 4 (338.6 mg, 61%) was obtained as a white solid.

As the paragraph descriping shows that 6624-49-3 is playing an increasingly important role.

Reference£º
Article; Gao, Fei; Liu, Haiqing; Li, Li; Guo, Jianpeng; Wang, Yuji; Zhao, Ming; Peng, Shiqi; Bioorganic and Medicinal Chemistry Letters; vol. 25; 20; (2015); p. 4434 – 4436;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.22246-02-2,6-Chloro-3,4-dihydroisoquinolin-1(2H)-one,as a common compound, the synthetic route is as follows.

[B] [5-(6-Chloro-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-pyridin-3-yl]-acetic acid (5-Bromo-pyridin-3-yl)-acetic acid methyl ester (230 mg, 1.0 mmol), 6-chloro-3,4-dihydro-2H-isoquinolin-1-one (intermediate A-2) (182 mg, 1.0 mmol), CuI (40 mg, 0.21 mmol), Cs2CO3 (650 mg, 2.0 mmol) and (+)-(1S,1S)-1,2-diaminocyclohexane (0.1 mL, 0.8 mmol) were dissolved in dioxane (4.0 ml) and the resulting reaction mixture was heated at 150 C. for 2 hours before it was poured into H2O (20 mL) and extracted with EtOAc (2*100 mL). The combined organic layer was washed with brine, dried over anhy. Na2SO4, filtered and concentrated in vacuo to give a crude product (230 mg, 72.5%) as light brown oil. MS: 317.1 (M+H+)., 22246-02-2

22246-02-2 6-Chloro-3,4-dihydroisoquinolin-1(2H)-one 19375637, aisoquinoline compound, is more and more widely used in various fields.

Reference£º
Patent; Hoffmann-La Roche Inc.; Aebi, Johannes; Amrein, Kurt; Chen, Wenming; Hornsperger, Benoit; Kuhn, Bernd; Liu, Yongfu; Maerki, Hans P.; Mayweg, Alexander V.; Mohr, Peter; Tan, Xuefei; Wang, Zhanguo; Zhou, Mingwei; US2013/143863; (2013); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

1532-97-4, 4-Bromoisoquinoline is a isoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Potassium nitrate (5.34 g; 0.052 mol) was added to 20 mL of concentrated sulfuric acid and slowly dissolved by careful heating. The resulting solution was added dropwise to a solution of 4-bromoisoquinoline (10 g, 0.048 mol) dissolved in 40 mL of the same acid at 0¡ã C. After removal of the cooling bath, the solution was stirred for one hour at room temperature. The reaction mixture was then poured onto crushed ice (400 g) and made basic with ammonium hydroxide. The resulting yellow precipitate was collected by filtration and the filtrate was extracted with diethyl ether (3*500 muL), dried (Na2SO4), and concentrated to give a yellow solid that was combined with the initial precipitate. Recrystallization from methanol gave 12.1 g (89percent) of 11 as slightly yellow crystals: mp 172-174¡ã C.; 1H NMR (300 MHz, CDCl3) delta 9.27 (s, 1H); 8.87 (s, 1H); 8.21 (dd, 1H, J=6.6, 1.2 Hz); 7.96 (dd, 1H, J=6.6, 1.2 Hz); 7.73 (t, 1H, J=7.5 Hz); CIMS m/z 253 (M+H+, 100percent); 255 (M+H++2, 100percent); Anal. Calc’d for C9H5BrN2O2: C, 42.72; H, 1.99; N, 11.07. Found: C, 42.59; H, 1.76; N, 10.87., 1532-97-4

1532-97-4 4-Bromoisoquinoline 73743, aisoquinoline compound, is more and more widely used in various fields.

Reference£º
Patent; DarPharma, Inc.; US2007/155720; (2007); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem